Table 4 Summary statistics of age, free prostate specific antigen (fPSA), total PSA (tPSA), free to total PSA (f/tPSA) and prostate cancer antigen 3 (PCA3) of the subjects included in the PCa study, grouped by the prostate biopsy histological results
|  | N (%) | Age mean ± SD | fPSA (μg/L) Median (IQR) (n = 142) | tPSA (μg/L) Median (IQR) (n = 142) | f/tPSA (μg/L) Median (IQR) (n = 142) | PCA3 score Median (IQR) (n = 142) |
|---|---|---|---|---|---|---|
No alterations | 57 (38.5%) | 65.3 ± 6.7 | 0.74 (0.43–1.36) | 5.05 (3.6–7.75) | 15.7 (10.10–19.40) | 23.50 (13.00–46.50) |
BPH | 7 (4.7%) | 65.8 ± 8.3 | 1.50 (0.9–2.17) | 7.01 (4.46–14.6) | 17.00 (14.90–19.00) | 49.00 (44.50–82.50) |
Inflammation | 12 (8.1%) | 66.2 ± 4.3 | 0.47 (0.26––0.93) | 4.00 (2.17–8.04) | 11.00 (9.15–16.20) | 22.00 (19.00–48.00) |
AAH | 2 (1.4%) | 61.5 ± 0.7 | 0.47 (0.26–1.00) | 7.13 (4.97–9.3) | 6.45 (4.70–8.20) | 21.50 (20.25–22.75) |
ASAP | 11 (7.4%) | 64.7 ± 7.8 | 0.71 (0.48–1.10) | 7.88 (3.85–9.16) | 11.40 (9.60–15.70) | 19.5 (14.5–32.00) |
HGPIN | 4 (2.7%) | 69.0 ± 5.0 | 0.49 (0.25–1.35) | 5.07 (4.11–5.83) | 10.50 (6.30–22.40) | 41.00 (26.00–70.00) |
PCa | 55 (37.2%) | 66.8 ± 7.1 | 0.43 (0.27–0.83) | 6.54 (4.08–9.23) | 8.10 (5.30–11.13) | 50.00 (24.00–88.00) |